Annals of Hematology

, Volume 66, Issue 2, pp 93–95

Monoclonal gammopathy of unknown significance in a bone marrow donor

  • S. O. Peters
  • M. Stockschläder
  • W. Zeller
  • K. Mross
  • M. Dürken
  • W. Krüger
  • A. R. Zander
Case Report

Abstract

We report on a patient suffering from multiple myeloma, for whom allogeneic bone marrow transplantation was planned. Donor workup revealed monoclonal gammopathy of unknown significance. We discuss this finding and stress the importance of performing complete donor examinations.

Key words

Bone marrow transplantation (BMT) Donor selection Monoclonal gammopathy of unknown significance (MGUS) Multiple myeloma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alexanian R, Haut A, Khan AU, Lane M, McKelvey E, Migliore P, Stuckey W, Wilson H (1969) Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 208: 1680–1685Google Scholar
  2. 2.
    Bersagel DE, Bailey AJ, Langley GR, McDonald R, White D, Miller A (1979) The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N Engl J Med 301: 743–748Google Scholar
  3. 3.
    Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC, Sullivan KM, Witherspoon RP, Deeg HJ, Appelbaum FR, Storb R, Thomas ED (1984) Marrow harvesting from normal donors. Blood 64: 630–634Google Scholar
  4. 4.
    Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, Facon T, Granena A, Gore M, Gratwohl A, Löwenberg B, Nikoskelainen J, Reiffers JJ, Samson D, Verdonck L, Volin L (1991) Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 325: 1267–1273Google Scholar
  5. 5.
    Gregory WM, Richards MA, Malpas JS (1992) Combination Chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: 334–342Google Scholar
  6. 6.
    Jagannath S, Jagannath S, Barlogie B (1992) Autologous bone marrow transplantation for multiple myeloma. Hematol Oncol Clin North Am 6: 437–449Google Scholar
  7. 7.
    Mandelli F, Avvisati G, Amadori S, Boccadori M, Gernone A, Lauta V, Marmont F, Petrucci M, Tribalto M, Vegna M, Damacco F, Pileri A (1990) Maintenance treatment with recombinant interferon α-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322: 1430–1434Google Scholar
  8. 8.
    Nietwieser DW, Appelbaum FR, Gastl G, Gersdorf E, Meister B, Geissler D, Tratkiewicz JA, Thaler J, Huber C (1990) Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med 322: 1794–1796Google Scholar
  9. 9.
    Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, Conell MJ (1990) Chemotherapy plus interferon (rIFN-α 2) in the treatment of multiple myeloma. Proc Am Aoc Clin Oncol 9: 288 (abstract 1116)Google Scholar
  10. 10.
    Osgood EE (1960) The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep: 1–10Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • S. O. Peters
    • 1
  • M. Stockschläder
    • 1
  • W. Zeller
    • 1
  • K. Mross
    • 1
  • M. Dürken
    • 1
  • W. Krüger
    • 1
  • A. R. Zander
    • 1
  1. 1.Zentrum für KnochenmarktransplantationUniversitätskrankenhaus EppendorfHamburg 20Germany

Personalised recommendations